Niagen Bioscience Inc

Niagen Bioscience Inc(NAGE)股票分析

$3.170

+0.061 (+1.93%)收盤時

Loading chart…
High
3.170
Open
3.090
VWAP
3.14
Vol
256.76K
Mkt Cap
Low
3.070
Amount
805.39K
EV/EBITDA, TTM
35.10

Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities.

AI analysis of Niagen Bioscience Inc (NAGE)

buy

Niagen Bioscience, Inc. appears to be a good buy right now due to its current price of $3.29, which is significantly lower than the analyst price target of $10, suggesting a potential upside of over 200%. Additionally, the company has a strong gross margin of 64.84% and a recent RSI of 63.87, indicating positive momentum. However, the main risk is the recent decline in revenue, with a year-to-date change of -47.36%.

估值指標

The current forward P/E ratio for Niagen Bioscience Inc (NAGE) is 22.37, compared to its 5-year average forward P/E of 42.08.

Forward P/E

Fair
5Y Average P/E
42.08
Current P/E
22.37
高估
68.99
低估
15.17

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
30.34
Current EV/EBITDA
35.10
高估
44.04
低估
16.64

Forward P/S

Undervalued
5Y Average P/S
3.69
Current P/S
1.62
高估
5.50
低估
1.88

Alphio AI Price Scenarios for NAGE

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NAGE

$14.51

情境價格

B

Base

Base · 50%NAGE

$12.61

情境價格

B

Bear

Bear · 25%NAGE

$10.88

情境價格

Whales holding NAGE

S

SteelPeak Wealth, LLC

+ HoldingNAGE

+2.27%

3M Return

事件時間軸

2026-08-20 (ET)

09:00:00

Niagen Bioscience's Tru Niagen Now Available at GNC and Sam's Club

2026-08-12 (ET)

10:00:00

Niagen Bioscience CFO Discusses NAD Strategy and Future Developments

2026-08-06 (ET)

14:30:00

Niagen Bioscience CFO Discusses Company Strategy and New Ventures

2026-08-03 (ET)

09:00:00

Niagen Bioscience Selects Evotec to Support NB4168 Development

2026-07-28 (ET)

09:00:00

Niagen Bioscience Publishes New Study Analysis

資訊

NAGE FAQ — answered by Alphio AI

Niagen Bioscience, Inc. is a global bioscience company promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredient, Niagen directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment comprises pharmaceutical development of its proprietary molecules for potential therapeutic applications in rare diseases and conducts research and development activities. It operates in the Healthcare sector.

Niagen Bioscience, Inc. appears to be a good buy right now due to its current price of $3.29, which is significantly lower than the analyst price target of $10, suggesting a potential upside of over 200%. Additionally, the company has a strong gross margin of 64.84% and a recent RSI of 63.87, indicating positive momentum. However, the main risk is the recent decline in revenue, with a year-to-date change of -47.36%.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始